# PNMT

## Overview
The PNMT gene encodes the enzyme phenylethanolamine N-methyltransferase, which is a member of the methyltransferase family. This enzyme is pivotal in the biosynthesis of catecholamines, specifically catalyzing the conversion of norepinephrine to epinephrine, a critical step in the stress response pathway (Kaneda1988Molecular; Georgieva2009The). PNMT is primarily expressed in the adrenal medulla's chromaffin cells and certain regions of the central nervous system, where it influences various physiological processes, including blood pressure regulation and neurotransmitter activity (Kaneda1988Molecular; Georgieva2009The). The enzyme's structure and function are modulated by several factors, including glucocorticoids and nerve growth factor, and it interacts with various ligands and inhibitors, which can affect its activity (Gee2007Enzyme; Kaneda1988Molecular). Genetic variations in the PNMT gene have been linked to several health conditions, such as hypertension and Alzheimer's disease, highlighting its clinical significance (Mann2001Phenylethanolamine; RodríguezFlores2010Conserved).

## Structure
The human phenylethanolamine N-methyltransferase (PNMT) enzyme is involved in the biosynthesis of epinephrine from norepinephrine. Its molecular structure has been extensively studied through crystallographic analysis, revealing key insights into its active site and catalytic mechanism. The enzyme's active site includes critical residues such as Asp267, Glu219, and Glu185, which play significant roles in substrate positioning and catalysis (Gee2005Mode; Drinkwater2009Molecular). 

Asp267 is particularly important for substrate alignment, interacting with the β-hydroxyl group of substrates to ensure proper positioning for methylation (Gee2005Mode; Wu2005Structural). Glu185 is identified as a key catalytic residue, with mutations at this position significantly affecting enzyme activity (Drinkwater2009Molecular). The enzyme's structure allows for the accommodation of various substrates, including multi-fused ring systems, highlighting its adaptability (Drinkwater2009Molecular).

PNMT's tertiary structure forms a specific three-dimensional shape crucial for its enzymatic activity, and it may undergo post-translational modifications such as phosphorylation. The enzyme is part of the methyltransferase family and may have different isoforms due to alternative splicing, although specific details on these isoforms are not provided in the context.

## Function
Phenylethanolamine N-methyltransferase (PNMT) is an enzyme that plays a critical role in the biosynthesis of catecholamines by catalyzing the conversion of norepinephrine to epinephrine. This reaction represents the final step in catecholamine biosynthesis and is dependent on S-adenosyl-L-methionine (AdoMet) as the methyl donor (Kaneda1988Molecular; Georgieva2009The). PNMT is predominantly located in the chromaffin cells of the adrenal medulla, where it facilitates the synthesis of epinephrine, a hormone crucial for the body's response to stress (Kaneda1988Molecular; Georgieva2009The).

In the central nervous system, PNMT is found in adrenergic neurons of the medulla oblongata and hypothalamus, where epinephrine functions as a neurotransmitter involved in regulating blood pressure, respiration, and hormone secretion from the pituitary gland (Kaneda1988Molecular; Georgieva2009The). The enzyme's activity is modulated by glucocorticoids and can be induced by nerve growth factor, highlighting its regulation by both hormonal and neural factors (Kaneda1988Molecular). PNMT's function in the brain, although less understood, is implicated in various physiological processes and may contribute to neurodegenerative conditions such as Alzheimer's disease (Georgieva2009The).

## Clinical Significance
Mutations and alterations in the PNMT gene have been associated with various diseases and conditions. Genetic variations in the PNMT promoter region, such as the SNPs G-367A and G-161A, can disrupt regulatory motifs and affect transcription factor binding, leading to altered gene expression. These changes have been linked to hypertension in African-Americans, early-onset Alzheimer's disease, multiple sclerosis, and reward dependence temperament (RodríguezFlores2010Conserved). However, some studies did not find an association with hypertension in European and European-American populations (Kepp2007Resequencing).

In sickle cell disease (SCD) patients, certain PNMT gene polymorphisms, including rs2934965, rs2941523, and rs876493, are associated with a reduced frequency of acute pain crises. These SNPs may alter transcription factor binding sites, potentially affecting PNMT expression and leading to lower epinephrine levels, which could reduce vaso-occlusive crises (Sadhu2020Phenylethanolamine).

The PNMT gene has also been implicated in early-onset Alzheimer's disease, with specific promoter polymorphisms showing a significant association with the condition (Mann2001Phenylethanolamine). Despite these associations, no distinct metabolic or clinical phenotype has been directly linked to PNMT dysfunction (Haavik2008Mutations).

## Interactions
Phenylethanolamine N-methyltransferase (PNMT) interacts with various ligands and inhibitors, which influence its enzymatic activity. The enzyme's binding site is flexible, allowing it to accommodate different substrates and inhibitors. This flexibility is partly due to the active site residue Lys57, which undergoes conformational changes to facilitate the binding of large inhibitors. These changes can reveal a cryptic binding site, enhancing the binding affinity of certain compounds (Gee2007Enzyme).

PNMT's interaction with inhibitors is also influenced by specific residues such as Glu219 and Asp267, which form hydrogen bonds and salt bridges with ligands. These interactions are crucial for stabilizing the binding of inhibitors and substrates, affecting the enzyme's activity (Nair2011Using). The presence of conserved water molecules in the binding pocket further mediates interactions with active-site residues, suggesting potential areas for inhibitor development (Drinkwater2010Fragmentbased).

Mutations in key residues, such as the substitution of Tyr35 with Phe, can decrease binding affinity by disrupting water-mediated interactions, highlighting the importance of these interactions in ligand recognition (Nair2011Using). These structural insights are essential for understanding PNMT's role in neurotransmitter regulation and for developing therapeutic inhibitors.


## References


[1. (Gee2005Mode) Christine L. Gee, Joel D. A. Tyndall, Gary L. Grunewald, Qian Wu, Michael J. McLeish, and Jennifer L. Martin. Mode of binding of methyl acceptor substrates to the adrenaline-synthesizing enzyme phenylethanolamine n-methyltransferase: implications for catalysis. Biochemistry, 44(51):16875–16885, December 2005. URL: http://dx.doi.org/10.1021/bi051636b, doi:10.1021/bi051636b. This article has 20 citations and is from a peer-reviewed journal.](https://doi.org/10.1021/bi051636b)

[2. (Kaneda1988Molecular) N Kaneda, H Ichinose, K Kobayashi, K Oka, F Kishi, A Nakazawa, Y Kurosawa, K Fujita, and T Nagatsu. Molecular cloning of cdna and chromosomal assignment of the gene for human phenylethanolamine n-methyltransferase, the enzyme for epinephrine biosynthesis. Journal of Biological Chemistry, 263(16):7672–7677, June 1988. URL: http://dx.doi.org/10.1016/s0021-9258(18)68551-5, doi:10.1016/s0021-9258(18)68551-5. This article has 59 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1016/s0021-9258(18)68551-5)

[3. (Haavik2008Mutations) Jan Haavik, Nenad Blau, and Beat Thöny. Mutations in human monoamine-related neurotransmitter pathway genes. Human Mutation, 29(7):891–902, July 2008. URL: http://dx.doi.org/10.1002/humu.20700, doi:10.1002/humu.20700. This article has 74 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1002/humu.20700)

[4. (Wu2005Structural) Qian Wu, Christine L. Gee, Frank Lin, Joel D. Tyndall, Jennifer L Martin, Gary L. Grunewald, and Michael J. McLeish. Structural, mutagenic, and kinetic analysis of the binding of substrates and inhibitors of human phenylethanolaminen-methyltransferase. Journal of Medicinal Chemistry, 48(23):7243–7252, October 2005. URL: http://dx.doi.org/10.1021/jm050568o, doi:10.1021/jm050568o. This article has 20 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1021/jm050568o)

[5. (Mann2001Phenylethanolamine) Michael B. Mann, Shijuan Wu, Massud Rostamkhani, Wallace Tourtellotte, James MacMurray, and David E. Comings. Phenylethanolamine n‐methyltransferase (pnmt) gene and early‐onset alzheimer disease. American Journal of Medical Genetics, 105(4):312–316, April 2001. URL: http://dx.doi.org/10.1002/ajmg.1363, doi:10.1002/ajmg.1363. This article has 28 citations.](https://doi.org/10.1002/ajmg.1363)

[6. (Georgieva2009The) Polina Georgieva, Qian Wu, Michael J. McLeish, and Fahmi Himo. The reaction mechanism of phenylethanolamine n-methyltransferase: a density functional theory study. Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics, 1794(12):1831–1837, December 2009. URL: http://dx.doi.org/10.1016/j.bbapap.2009.08.022, doi:10.1016/j.bbapap.2009.08.022. This article has 26 citations.](https://doi.org/10.1016/j.bbapap.2009.08.022)

[7. (Gee2007Enzyme) Christine L. Gee, Nyssa Drinkwater, Joel D. A. Tyndall, Gary L. Grunewald, Qian Wu, Michael J. McLeish, and Jennifer L. Martin. Enzyme adaptation to inhibitor binding: a cryptic binding site in phenylethanolamine n-methyltransferase. Journal of Medicinal Chemistry, 50(20):4845–4853, September 2007. URL: http://dx.doi.org/10.1021/jm0703385, doi:10.1021/jm0703385. This article has 23 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1021/jm0703385)

[8. (Nair2011Using) Pramod C. Nair, Alpeshkumar K. Malde, and Alan E. Mark. Using theory to reconcile experiment: the structural and thermodynamic basis of ligand recognition by phenylethanolamine n-methyltransferase (pnmt). Journal of Chemical Theory and Computation, 7(5):1458–1468, March 2011. URL: http://dx.doi.org/10.1021/ct1007229, doi:10.1021/ct1007229. This article has 13 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1021/ct1007229)

[9. (Kepp2007Resequencing) Katrin Kepp, Peeter Juhanson, Viktor Kozich, Mai Ots, Margus Viigimaa, and Maris Laan. Resequencing pnmtin european hypertensive and normotensive individuals: no common susceptibilily variants for hypertension and purifying selection on intron 1. BMC Medical Genetics, July 2007. URL: http://dx.doi.org/10.1186/1471-2350-8-47, doi:10.1186/1471-2350-8-47. This article has 11 citations and is from a peer-reviewed journal.](https://doi.org/10.1186/1471-2350-8-47)

[10. (RodríguezFlores2010Conserved) Juan L. Rodríguez-Flores, Kuixing Zhang, Sun Woo Kang, Gen Wen, Sajalendu Ghosh, Ryan S. Friese, Sushil K. Mahata, Shankar Subramaniam, Bruce A. Hamilton, and Daniel T. O’Connor. Conserved regulatory motifs at phenylethanolamine n-methyltransferase (pnmt) are disrupted by common functional genetic variation: an integrated computational/experimental approach. Mammalian Genome, 21(3–4):195–204, March 2010. URL: http://dx.doi.org/10.1007/s00335-010-9253-y, doi:10.1007/s00335-010-9253-y. This article has 7 citations and is from a peer-reviewed journal.](https://doi.org/10.1007/s00335-010-9253-y)

[11. (Sadhu2020Phenylethanolamine) Nilanjana Sadhu, Ellie H Jhun, Andrew Posen, Yingwei Yao, Ying He, Robert E Molokie, Diana J Wilkie, and Zaijie J Wang. Phenylethanolamine n -methyltransferase gene polymorphisms associate with crisis pain in sickle cell disease patients. Pharmacogenomics, 21(4):269–278, March 2020. URL: http://dx.doi.org/10.2217/pgs-2019-0096, doi:10.2217/pgs-2019-0096. This article has 6 citations and is from a peer-reviewed journal.](https://doi.org/10.2217/pgs-2019-0096)

[12. (Drinkwater2009Molecular) Nyssa Drinkwater, Christine L. Gee, Munish Puri, Kevin R. Criscione, Michael J. McLeish, Gary L. Grunewald, and Jennifer L. Martin. Molecular recognition of physiological substrate noradrenaline by the adrenaline-synthesizing enzyme pnmt and factors influencing its methyltransferase activity. Biochemical Journal, 422(3):463–471, August 2009. URL: http://dx.doi.org/10.1042/bj20090702, doi:10.1042/bj20090702. This article has 29 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1042/bj20090702)

[13. (Drinkwater2010Fragmentbased) Nyssa Drinkwater, Hoan Vu, Kimberly M. Lovell, Kevin R. Criscione, Brett M. Collins, Thomas E. Prisinzano, Sally-Ann Poulsen, Michael J. McLeish, Gary L. Grunewald, and Jennifer L. Martin. Fragment-based screening by x-ray crystallography, ms and isothermal titration calorimetry to identify pnmt (phenylethanolamine n-methyltransferase) inhibitors. Biochemical Journal, 431(1):51–61, September 2010. URL: http://dx.doi.org/10.1042/bj20100651, doi:10.1042/bj20100651. This article has 37 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1042/bj20100651)